An Engineered Nanoimmunotherapy for Treating Neuroblastoma |
George Washington University / Rohan Fernandes, PhD |
'A' Award Grants |
2016 |
District of Columbia |
Exploiting the Differentiation Potential of Pediatric High-Grade Glioma to Discover Novel Therapeutic Opportunities |
Dana-Farber Cancer Institute / Mariella Filbin, MD/PhD |
'A' Award Grants |
2019 |
Massachusetts |
Inside-Out Immunotherapy: Combating Neuroblastoma via Nanoparticle-Directed Reprogramming of the Tumor Microenvironment |
Vanderbilt University Medical Center / John Wilson, PhD |
'A' Award Grants |
2015 |
Tennessee |
Characterizing the Developmental Context of Pediatric Leukemia
|
Icahn School of Medicine at Mount Sinai / Elvin Wagenblast, PhD |
'A' Award Grants |
2022 |
New York |
Prognostic and Therapeutic Significance of Stem Cell Heterogeneity in AML |
Fred Hutchinson Cancer Research Center / Roland Walter, MD, PhD |
'A' Award Grants |
2012 |
Washington |
Epigenetic Modifiers as Therapeutic Targets in Pediatric T-cell Acute Lymphoblastic Leukemia |
Washington University / Grant Challen, PhD |
'A' Award Grants |
2012 |
Missouri |
Genetic Susceptibility to Pediatric Osteosarcoma and Interaction with Measures of Childhood Growth |
Duke University / Kyle Walsh, Ph.D. |
'A' Award Grants |
2014 |
North Carolina |
Functional Characterization of RELA Fusion Ependymoma as a Basis for Therapeutic Targeting |
St. Jude Children’s Research Hospital / Stephen Mack, PhD |
'A' Award Grants |
2018 |
Tennessee |
Exploiting glypican diversity in neuroblastoma plasticity with bicistronic CAR T cell targeting |
Children’s Hospital of Philadelphia / Kristopher Bosse, MD |
'A' Award Grants |
2022 |
Pennsylvania |
Rational Combination Therapy of AML |
Memorial Sloan-Kettering Cancer Center / Alex Kentsis, MD, PhD |
'A' Award Grants |
2013 |
New York |